Allergan Plc's ROA from the first quarter of 2020 to the first quarter of 2019 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Allergan Plc's ROA in the first quarter of 2020?
Allergan Plc had a negative return on assets (ROA) of -2.66%, due to the net loss of $-2 billion, during the twelve months ending in the first quarter of 2020.

However, within the Healthcare sector 227 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2020 quarter, so far to 2951, from total ROA ranking in the fourth quarter of 2019 at 3728.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2020) I. Quarter	(Dec 31 2019) IV. Quarter	(Sep 30 2019) III. Quarter	(Jun 30 2019) II. Quarter	(Mar 31 2019) I. Quarter
Y / Y Total Assets Change	-9.8 %	-6.18 %	-11.25 %	-12.14 %	-12.43 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-2,479	-5,265	-9,244	-8,494	-7,210
Return On Assets (TTM)	-2.66 %	-5.5 %	-9.51 %	-8.48 %	-6.97 %
AGN's Total Ranking	# 2951	# 3728	# 3551	# 3548	# 3551
Total Assets (TTM) in million	88,426	94,671	94,409	95,481	98,036
Seq. Total Assets Change	-6.6 %	0.28 %	-1.12 %	-2.61 %	-2.84 %
Seq. Net Income Change	-	-	-	-	-

AGN's 5 Years Annual ROA >> Back to AGN Management Effectiveness >> Compare AGN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 71
Sector	# 228
Overall	# 2851

Return On Assets Statistics
High	Average	Low
15.84 %	5.12 %	-9.49 %
(Sep. 30, 2005)		(Sep 30 2019)

Financial Statements
Allergan Plc's Assets	$ 88,426 million	AGN's Balance sheet
Allergan Plc's Income	$ 379 million	Quarterly AGN's Income Statement
AGN's Income by Division		See AGN's Income by Division

Annual Return On Assets	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2017) FY 2017	(Dec 31 2016) FY 2016	(Dec 31 2015) FY 2015
Y / Y Total Assets Change	-6.15 %	-14.68 %	-8.3 %	-5.07 %	994.1 %
Total Assets in million	94,699	100,905	118,260	128,959	135,841
Y / Y Net Income Change	-	-	-	282.19 %	157.14 %
Net Income in million	-5,265	-5,086	-4,119	14,980	3,919
Annual Return On Assets	-5.56 %	-5.04 %	-3.48 %	11.62 %	2.89 %

AGN's 5 Years Annual ROA >> Back to AGN Management Effectiveness >> Compare AGN ROA to its Competitors

More Return On Assets Ratios
AGN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AGN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AGN's Competitors
Subscribers only: Roa for Allergan Plc's Suppliers
Subscribers only: Return On Assets for AGN's Customers

You may also want to know
AGN's Roi	AGN's Inventory Turnover Ratio	AGN's Growth Rates	AGN's Dividend Comparisons
	AGN's Profitability Ratios	AGN's Asset Turnover Ratio	AGN's Dividend Growth
AGN's Roe	AGN's Valuation Ratios	AGN's Financial Strength Ratios	AGN's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2020, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:20:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.